Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

We apply an entrepreneurial spirit to everything we do. We build long lasting relationships with our clients based on mutual trust. Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.

Vator Securities is led by experienced professionals who have between 15 to 25 years of capital market and advisory experience from some of the world’s most prominent investment banks. Our service offering includes:

  • ​Pre-IPO Financing
  • IPOs and Secondaries
  • Capital Markets Advisory
  • Strategic Advisory
  • Equity Research

Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family offices and high net worth investors. The unique network of investors implies that Vator Securities can source capital irrespective of financial market sentiments and create liquidity in the stock post IPO.

At Vator Securities every project is more than a single transaction. We specialize in providing partnerships where we work long-term with the client and support the value creation of a company long before a transaction commences. We focus on building a long-term strategy for our clients by guiding and consulting extensively throughout the entire life cycle – from idea to completion, but also through follow-ups and post transaction consulting and support.

Respiratorius

SEK 25m | Directed Share Issue | Q2 2021

Financial Adviser

Sprint Bioscience

SEK 21m | Directed Share Issue | Q2 2021

Financial Adviser

CombiGene

SEK 75m | Rights Issue | Q1 2021

Financial Adviser

SiB Solutions

SEK 23m | Private Placement | Q4 2020

Financial Adviser

Xintela

SEK 37m | Warrants | Q4 2020

Financial Adviser

NextCell Pharma

SEK 150m | Rights Issue | Q4 2020

Financial Adviser

Scandion Oncology

SEK 236m | Rights Issue | Q4 2020

Financial Adviser

Moberg Pharma

SEK 150m | Rights Issue | Q4 2020

Financial Adviser

SciBase

SEK 32m | Warrants | Q4 2020

Financial Adviser

A3P Biomedical

SEK 110m | Private Placement | Q3 2020

Financial Adviser

Fundler

SEK 17m | Private Placement | Q2 2020

Financial Adviser

Xintela

SEK 40,5m | Rights Issue | Q2 2020

Financial Adviser

LIDDS

SEK 59,3m | Directed & Rights Issue | Q2 2020

Sole Bookrunner

Immunovia

SEK 400m | Directed Share Issue | Q2 2020

Joint Bookrunner

Xbrane Biopharma

SEK 146m | Directed Share Issue | Q2 2020

Global Coordinator and Sole Bookrunner

NextCell Pharma

SEK 25m | Rights Issue | Q2 2020

Financial Adviser

SciBase Holding

SEK 25m | Rights Issue | Q2 2020

Financial Adviser

Plastics Unbound

SEK 21,7m | Private Placement | Q4 2019

Financial Adviser

SenzaGen

SEK 106m | Directed & Rights Issue | Q4 2019

Sole Bookrunner

Nanoform

SEK 106m | Private Placement | Q2 2019

Financial Adviser

Empros Pharma

SEK 40m | Private Placement | Q2 2019

Financial Adviser

Xbrane Biopharma

SEK 238m | Directed & Rights Issue | Q2 2019

Sole Bookrunner

Bio-Works

SEK 70m | Directed & Rights Issue | Q2 2019

Sole Bookrunner

Xbrane Biopharma

SEK 59m | Rights Issue | Q1 2019

Financial Adviser

Ascelia Pharma

SEK 200m | IPO | Q1 2019

Sole Global Coordinator and Bookrunner

AlzeCure

SEK 200m | IPO | Q4 2018

Sole Global Coordinator and Bookrunner

Nanoform

SEK 71m | Private Placement | Q2 2018

Financial Adviser

AlzeCure

SEK 40m | Private Placement | Q2 2018

Financial Adviser

Immunovia

SEK 324m | Direct share issue | Q2 2018

Sole Bookrunner

Plastics Unbound


SEK 50m | Private Placement | Q2 2018

Financial Adviser

Ascelia Pharma

SEK 60m | Private Placement | Q1 2018

Financial Adviser

Bio-Works

SEK 80m | IPO | Q4 2017

Sole Bookrunner

IRRAS

SEK 334m | IPO | Q4 2017

Financial Advisor

SenzaGen

SEK 90,1m | IPO | Q3 2017

Sole Bookrunner

TerraNet

SEK 100m | IPO | Q2 2017

Sole Bookrunner

Bio-Works

SEK 30m | Private Placement | Q2 2017

Financial Adviser

AlzeCure

SEK 70m | Private Placement | Q2 2017

Financial Adviser

Biovica

SEK 60m | IPO | Q1 2017

Sole Bookrunner

Acarix

SEK 140,4m | IPO | Q4 2016

Sole Bookrunner

Immunovia

SEK 189,9m + 28,7m | Q3 2016

Private Placement & Rights Issue

Sole Bookrunner

Xbrane Biopharma

SEK 100m | IPO Q4 | 2015

Sole Bookrunner

Vikingaliv

SEK 113,6m | Private Placement | Q2 2015

Financial Adviser